Novavax Inc. closed 68.94% below its 52-week high of $23.86, which the company achieved on June 6th.

B. Riley decreased their FY2024 earnings estimates for Novavax in a report issued on Thursday, February 20th. B. Riley ...

Stocks of makers of COVID vaccines, Moderna MRNA, Pfizer PFE, Novavax NVAX and BioNTech BNTX rose on Friday on reports of a new bat coronavirus being discovered in China. What is the New Coronavirus?

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Bullish option flow detected in Novavax (NVAX) with 23,789 calls trading, 3x expected, and implied vol increasing over 8 points to 114.25%.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial ...

Novavax (NVAX) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%. At ...

Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, the company’s earnings beat estimates by 12.64%. The Zacks Consensus ...

Novavax Inc. closed 66.14% below its 52-week high of $23.86, which the company reached on June 6th.

In the closing of the recent trading day, Novavax (NVAX) stood at $8.19, denoting a +0.74% change from the preceding trading day. In the most recent trading session, Novavax (NVAX) closed at $8.45, ...